Breaking News Instant updates and real-time market news.

POL

PolyOne

$32.82 /

+0.46 (+1.42%)

16:36
10/15/19
10/15
16:36
10/15/19
16:36

PolyOne initiated with a Market Perform at Wells Fargo

Wells Fargo analyst Micheal Sison initiated coverage of PolyOne with a Market Perform rating and $35 price target. The analyst notes that although the company is generating "solid" earnings in 2019 while also delevering its balance sheet, it is lacking a "growth catalyst" to generate further multiple expansion. Sison adds that PolyOne is currently trading at an enterprise value to expected 2020 EBITDA multiple of 10-times vs. its 7-year valuation range of 8- to 11-times, adding that the higher end of that range was achieved when was company's growth rate was in double digits.

  • 22

    Oct

  • 30

    Oct

POL PolyOne
$32.82 /

+0.46 (+1.42%)

10/15/19 Wells Fargo
PolyOne initiated with a Market Perform at Wells Fargo
07/22/19
Fly Intel: Top five analyst upgrades
07/22/19 Baird
PolyOne upgraded to Outperform from Neutral at Baird
06/11/19 Wellington Shields
PolyOne upgraded to Gradually Accumulate from Hold at Wellington Shields

TODAY'S FREE FLY STORIES

Earnings
AdaptHealth sees FY20 revenue $935M-$983M, consensus $888.77M » 06:13
08/04/20
08/04
06:13
08/04/20
06:13
AHCO

AdaptHealth

$19.80 /

+0.41 (+2.11%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AHCO AdaptHealth
$19.80 /

+0.41 (+2.11%)

AHCO AdaptHealth
$19.80 /

+0.41 (+2.11%)

07/01/20 SVB Leerink
AdaptHealth initiated with an Outperform at SVB Leerink
06/09/20 RBC Capital
AdaptHealth initiated with an Outperform at RBC Capital
02/28/20 Deutsche Bank
AdaptHealth price target raised to $19 from $12 at Deutsche Bank
01/31/20
Fly Intel: Top five analyst initiations
AHCO AdaptHealth
$19.80 /

+0.41 (+2.11%)

  • 01
    Jul
Initiation
Fresnillo initiated with a Sell at Berenberg » 06:13
08/04/20
08/04
06:13
08/04/20
06:13
FNLPF

Fresnillo

$0.00 /

+ (+0.00%)

Berenberg analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FNLPF Fresnillo
$0.00 /

+ (+0.00%)

07/29/20 JPMorgan
Fresnillo price target raised to 800 GBp from 750 GBp at JPMorgan
07/29/20 BMO Capital
Fresnillo price target raised to 1,200 GBp from 1,125 GBp at BMO Capital
07/28/20 RBC Capital
Fresnillo price target raised to 1,300 GBp from 1,100 GBp at RBC Capital
07/23/20 BMO Capital
Fresnillo price target raised to 1,125 GBp from 875 GBp at BMO Capital
Earnings
Edgewell Personal Care reports Q3 adj. EPS 66c, consensus 82c » 06:13
08/04/20
08/04
06:13
08/04/20
06:13
EPC

Edgewell Personal Care

$30.91 /

+1.02 (+3.41%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EPC Edgewell Personal Care
$30.91 /

+1.02 (+3.41%)

EPC Edgewell Personal Care
$30.91 /

+1.02 (+3.41%)

02/28/20
Fly Intel: Top five analyst initiations
02/28/20 Goldman Sachs
Edgewell Personal Care reinstated with a Conviction Buy at Goldman Sachs
02/11/20 SunTrust
Edgewell Personal Care price target raised to $45 from $40 at SunTrust
02/10/20 Citi
Edgewell Personal Care downgraded to Neutral from Buy at Citi
EPC Edgewell Personal Care
$30.91 /

+1.02 (+3.41%)

EPC Edgewell Personal Care
$30.91 /

+1.02 (+3.41%)

Earnings
Gartner raises FY20 adjusted EPS view to 'at least' $3.08, consensus $3.03 » 06:13
08/04/20
08/04
06:13
08/04/20
06:13
IT

Gartner

$125.66 /

+1.19 (+0.96%)

Raises FY20 revenue view…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IT Gartner
$125.66 /

+1.19 (+0.96%)

IT Gartner
$125.66 /

+1.19 (+0.96%)

05/11/20 BMO Capital
Gartner price target raised to $122 from $100 at BMO Capital
03/27/20 BMO Capital
Gartner price target lowered to $100 from $113 at BMO Capital
03/25/20 BMO Capital
Gartner price target lowered to $113 from $121 at BMO Capital
03/10/20 BMO Capital
Gartner price target lowered to $121 from $158 at BMO Capital
IT Gartner
$125.66 /

+1.19 (+0.96%)

IT Gartner
$125.66 /

+1.19 (+0.96%)

Initiation
Poseida Therapeutics initiated with a Buy at BofA » 06:12
08/04/20
08/04
06:12
08/04/20
06:12
PSTX

Poseida Therapeutics

$13.47 /

-0.18 (-1.32%)

BofA analyst Geoff…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$13.47 /

-0.18 (-1.32%)

04:50 Today Piper Sandler
Poseida Therapeutics initiated with an Overweight at Piper Sandler
  • 10
    Jul
PSTX Poseida Therapeutics
$13.47 /

-0.18 (-1.32%)

Earnings
AdaptHealth reports Q2 EPS 8c, consensus 19c » 06:11
08/04/20
08/04
06:11
08/04/20
06:11
AHCO

AdaptHealth

$19.80 /

+0.41 (+2.11%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AHCO AdaptHealth
$19.80 /

+0.41 (+2.11%)

AHCO AdaptHealth
$19.80 /

+0.41 (+2.11%)

07/01/20 SVB Leerink
AdaptHealth initiated with an Outperform at SVB Leerink
06/09/20 RBC Capital
AdaptHealth initiated with an Outperform at RBC Capital
02/28/20 Deutsche Bank
AdaptHealth price target raised to $19 from $12 at Deutsche Bank
01/31/20
Fly Intel: Top five analyst initiations
AHCO AdaptHealth
$19.80 /

+0.41 (+2.11%)

  • 01
    Jul
Earnings
Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34 » 06:11
08/04/20
08/04
06:11
08/04/20
06:11
MNK

Mallinckrodt

$2.26 /

+0.025 (+1.12%)

Reports Q2 adjusted net…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MNK Mallinckrodt
$2.26 /

+0.025 (+1.12%)

MNK Mallinckrodt
$2.26 /

+0.025 (+1.12%)

07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
MNK Mallinckrodt
$2.26 /

+0.025 (+1.12%)

MNK Mallinckrodt
$2.26 /

+0.025 (+1.12%)

MNK Mallinckrodt
$2.26 /

+0.025 (+1.12%)

MNK Mallinckrodt
$2.26 /

+0.025 (+1.12%)

Upgrade
LyondellBasell upgraded to Neutral at BofA on underperformance » 06:10
08/04/20
08/04
06:10
08/04/20
06:10
LYB

LyondellBasell

$62.17 /

-0.35 (-0.56%)

BofA analyst Steve Byrne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LYB LyondellBasell
$62.17 /

-0.35 (-0.56%)

LYB LyondellBasell
$62.17 /

-0.35 (-0.56%)

06:04 Today BofA
LyondellBasell upgraded to Neutral from Underperform at BofA
06/29/20 Citi
LyondellBasell downgraded to Neutral on 'muted' U.S. advantage at Citi
06/29/20 Citi
LyondellBasell downgraded to Neutral from Buy at Citi
06/26/20 JPMorgan
LyondellBasell price target raised to $62 from $50 at JPMorgan
LYB LyondellBasell
$62.17 /

-0.35 (-0.56%)

LYB LyondellBasell
$62.17 /

-0.35 (-0.56%)

LYB LyondellBasell
$62.17 /

-0.35 (-0.56%)

Initiation
Brookfield Renewable initiated with an Overweight at Wells Fargo » 06:10
08/04/20
08/04
06:10
08/04/20
06:10
BEPC

Brookfield Renewable

$46.99 /

+2.06 (+4.58%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Earnings
Venator Materials reports Q2 adj. EPS (3c), consensus (8c) » 06:09
08/04/20
08/04
06:09
08/04/20
06:09
VNTR

Venator Materials

$1.84 /

+0.09 (+5.14%)

Reports Q2 revenue $456M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VNTR Venator Materials
$1.84 /

+0.09 (+5.14%)

04/21/20 BMO Capital
Venator Materials downgraded to Market Perform from Outperform at BMO Capital
04/08/20 Citi
Venator Materials price target lowered to $1.40 from $2.30 at Citi
03/30/20 Goldman Sachs
Venator Materials downgraded to Neutral from Buy at Goldman Sachs
03/23/20 Jefferies
Jefferies downgrades 10 'lower conviction' Chemicals stocks to Hold
VNTR Venator Materials
$1.84 /

+0.09 (+5.14%)

VNTR Venator Materials
$1.84 /

+0.09 (+5.14%)

Hot Stocks
Atkore sees FY20 adjusted EPS down 10% from last year » 06:09
08/04/20
08/04
06:09
08/04/20
06:09
ATKR

Atkore

$27.75 /

+1.09 (+4.09%)

The Company is currently…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ATKR Atkore
$27.75 /

+1.09 (+4.09%)

03/26/20 RBC Capital
Atkore downgraded to Sector Perform from Outperform at RBC Capital
03/26/20 RBC Capital
Atkore downgraded to Sector Perform from Outperform at RBC Capital
01/03/20 Wells Fargo
Acuity Brands price target raised to $155 from $138 at Wells Fargo
11/25/19 RBC Capital
Atkore price target raised to $46 from $32 at RBC Capital
ATKR Atkore
$27.75 /

+1.09 (+4.09%)

Earnings
Amarin reports Q2 adjusted EPS 4c, consensus (7c) » 06:08
08/04/20
08/04
06:08
08/04/20
06:08
AMRN

Amarin

$6.77 /

+0.285 (+4.39%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMRN Amarin
$6.77 /

+0.285 (+4.39%)

AMRN Amarin
$6.77 /

+0.285 (+4.39%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.77 /

+0.285 (+4.39%)

AMRN Amarin
$6.77 /

+0.285 (+4.39%)

AMRN Amarin
$6.77 /

+0.285 (+4.39%)

AMRN Amarin
$6.77 /

+0.285 (+4.39%)

Earnings
Atkore reports Q2 adjusted EPS 67c, consensus 48c » 06:08
08/04/20
08/04
06:08
08/04/20
06:08
ATKR

Atkore

$27.75 /

+1.09 (+4.09%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ATKR Atkore
$27.75 /

+1.09 (+4.09%)

03/26/20 RBC Capital
Atkore downgraded to Sector Perform from Outperform at RBC Capital
03/26/20 RBC Capital
Atkore downgraded to Sector Perform from Outperform at RBC Capital
01/03/20 Wells Fargo
Acuity Brands price target raised to $155 from $138 at Wells Fargo
11/25/19 RBC Capital
Atkore price target raised to $46 from $32 at RBC Capital
ATKR Atkore
$27.75 /

+1.09 (+4.09%)

Periodicals
COVID-19 vaccine candidates impress, but investors wary, WSJ reports » 06:07
08/04/20
08/04
06:07
08/04/20
06:07
MRNA

Moderna

$77.98 /

+3.88 (+5.24%)

, PFE

Pfizer

$38.36 /

-0.125 (-0.32%)

Potential COVID-19…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$77.98 /

+3.88 (+5.24%)

PFE Pfizer
$38.36 /

-0.125 (-0.32%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
PFE Pfizer
$38.36 /

-0.125 (-0.32%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
MRNA Moderna
$77.98 /

+3.88 (+5.24%)

PFE Pfizer
$38.36 /

-0.125 (-0.32%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$77.98 /

+3.88 (+5.24%)

PFE Pfizer
$38.36 /

-0.125 (-0.32%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

PFE Pfizer
$38.36 /

-0.125 (-0.32%)

MRNA Moderna
$77.98 /

+3.88 (+5.24%)

PFE Pfizer
$38.36 /

-0.125 (-0.32%)

Earnings
Gentherm not providing update to FY20 guidance » 06:07
08/04/20
08/04
06:07
08/04/20
06:07
THRM

Gentherm

$40.34 /

+1.58 (+4.08%)

As a result of the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
THRM Gentherm
$40.34 /

+1.58 (+4.08%)

THRM Gentherm
$40.34 /

+1.58 (+4.08%)

06/19/20 JPMorgan
Gentherm price target raised to $39 from $34 at JPMorgan
05/12/20 Barrington
Gentherm outperforming relative to automotive industry, says Barrington
05/11/20 Roth Capital
Gentherm assumed with a Buy at Roth Capital
04/21/20 Craig-Hallum
Gentherm price target lowered to $38 from $50 at Craig-Hallum
THRM Gentherm
$40.34 /

+1.58 (+4.08%)

Earnings
Haemonetics reports Q1 adj. EPS 46c, consensus 41c » 06:06
08/04/20
08/04
06:06
08/04/20
06:06
HAE

Haemonetics

$87.12 /

-0.58 (-0.66%)

Reports Q1 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HAE Haemonetics
$87.12 /

-0.58 (-0.66%)

HAE Haemonetics
$87.12 /

-0.58 (-0.66%)

07/01/20 Raymond James
Haemonetics price target lowered to $113 from $125 at Raymond James
05/06/20 Barrington
Haemonetics downgraded to Market Perform from Outperform at Barrington
04/07/20 Raymond James
Haemonetics price target lowered to $130 from $150 at Raymond James
03/20/20 Jefferies
Haemonetics 'key strategic provider' for plasma COVID approaches, says Jefferies
HAE Haemonetics
$87.12 /

-0.58 (-0.66%)

Earnings
Leidos raises FY20 EPS view to $5.25-$5.55 from $5.00-$5.30, consensus $5.24 » 06:06
08/04/20
08/04
06:06
08/04/20
06:06
LDOS

Leidos

$98.40 /

+3.32 (+3.49%)

Lowers FY20 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LDOS Leidos
$98.40 /

+3.32 (+3.49%)

LDOS Leidos
$98.40 /

+3.32 (+3.49%)

06/11/20
Fly Intel: Top five analyst initiations
06/11/20 Baird
Baird starts Leidos at Outperform, sees growth poised to ramp next year
06/10/20 Baird
Leidos initiated with an Outperform at Baird
05/07/20
Fly Intel: Top five analyst initiations
LDOS Leidos
$98.40 /

+3.32 (+3.49%)

LDOS Leidos
$98.40 /

+3.32 (+3.49%)

LDOS Leidos
$98.40 /

+3.32 (+3.49%)

Earnings
Gentherm sees Q3 product revenues $210M-$240M, consensus $212.53M  06:06
08/04/20
08/04
06:06
08/04/20
06:06
THRM

Gentherm

$40.34 /

+1.58 (+4.08%)

 
ShowHide Related Items >><<
THRM Gentherm
$40.34 /

+1.58 (+4.08%)

THRM Gentherm
$40.34 /

+1.58 (+4.08%)

06/19/20 JPMorgan
Gentherm price target raised to $39 from $34 at JPMorgan
05/12/20 Barrington
Gentherm outperforming relative to automotive industry, says Barrington
05/11/20 Roth Capital
Gentherm assumed with a Buy at Roth Capital
04/21/20 Craig-Hallum
Gentherm price target lowered to $38 from $50 at Craig-Hallum
THRM Gentherm
$40.34 /

+1.58 (+4.08%)

Upgrade
Zillow upgraded to Neutral from Negative at Susquehanna » 06:06
08/04/20
08/04
06:06
08/04/20
06:06
ZG

Zillow

$67.75 /

-0.21 (-0.31%)

Susquehanna analyst Shyam…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ZG Zillow
$67.75 /

-0.21 (-0.31%)

ZG Zillow
$67.75 /

-0.21 (-0.31%)

07/20/20 Goldman Sachs
Zillow price target raised to $58 from $47 at Goldman Sachs
07/17/20 JMP Securities
Zillow price target raised to $75 from $60 at JMP Securities
07/16/20 Craig-Hallum
Zillow price target raised to $67 from $60 at Craig-Hallum
06/10/20 BTIG
Zillow initiated with a Buy at BTIG
ZG Zillow
$67.75 /

-0.21 (-0.31%)

ZG Zillow
$67.75 /

-0.21 (-0.31%)

Earnings
Jeld-Wen reports Q2 adjusted EPS 47c, consensus 20c » 06:06
08/04/20
08/04
06:06
08/04/20
06:06
JELD

Jeld-Wen

$20.38 /

+0.71 (+3.61%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JELD Jeld-Wen
$20.38 /

+0.71 (+3.61%)

JELD Jeld-Wen
$20.38 /

+0.71 (+3.61%)

07/21/20 Benchmark
Jeld-Wen downgraded to Hold from Buy at Benchmark
07/10/20 JPMorgan
Jeld-Wen price target raised to $18 from $12 at JPMorgan
06/18/20 Benchmark
Jeld-Wen price target raised to $18 from $14 at Benchmark
05/27/20 Credit Suisse
Jeld-Wen initiated with an Underperform at Credit Suisse
JELD Jeld-Wen
$20.38 /

+0.71 (+3.61%)

Earnings
Gentherm reports Q2 adjusted EPS (30c), consensus (48c) » 06:05
08/04/20
08/04
06:05
08/04/20
06:05
THRM

Gentherm

$40.34 /

+1.58 (+4.08%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
THRM Gentherm
$40.34 /

+1.58 (+4.08%)

THRM Gentherm
$40.34 /

+1.58 (+4.08%)

06/19/20 JPMorgan
Gentherm price target raised to $39 from $34 at JPMorgan
05/12/20 Barrington
Gentherm outperforming relative to automotive industry, says Barrington
05/11/20 Roth Capital
Gentherm assumed with a Buy at Roth Capital
04/21/20 Craig-Hallum
Gentherm price target lowered to $38 from $50 at Craig-Hallum
THRM Gentherm
$40.34 /

+1.58 (+4.08%)

Downgrade
Neurocrine downgraded to Neutral on valuation at JPMorgan » 06:05
08/04/20
08/04
06:05
08/04/20
06:05
NBIX

Neurocrine

$123.17 /

+2.8 (+2.33%)

JPMorgan analyst Anupam…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

04:46 Today JPMorgan
Neurocrine downgraded to Neutral from Overweight at JPMorgan
07/23/20 Mizuho
Neurocrine price target raised to $127 from $105 at Mizuho
07/20/20 Credit Suisse
Neurocrine price target raised to $135 from $101 at Credit Suisse
07/17/20 Oppenheimer
Neurocrine price target raised to $152 from $142 at Oppenheimer
NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

Earnings
Leidos reports Q2 EPS $1.55, consensus $1.09 » 06:04
08/04/20
08/04
06:04
08/04/20
06:04
LDOS

Leidos

$98.40 /

+3.32 (+3.49%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LDOS Leidos
$98.40 /

+3.32 (+3.49%)

LDOS Leidos
$98.40 /

+3.32 (+3.49%)

06/11/20
Fly Intel: Top five analyst initiations
06/11/20 Baird
Baird starts Leidos at Outperform, sees growth poised to ramp next year
06/10/20 Baird
Leidos initiated with an Outperform at Baird
05/07/20
Fly Intel: Top five analyst initiations
LDOS Leidos
$98.40 /

+3.32 (+3.49%)

LDOS Leidos
$98.40 /

+3.32 (+3.49%)

LDOS Leidos
$98.40 /

+3.32 (+3.49%)

Hot Stocks
Louisiana-Pacific backs FY20 CapEx view approximately $70M » 06:04
08/04/20
08/04
06:04
08/04/20
06:04
LPX

Louisiana-Pacific

$31.40 /

-0.27 (-0.85%)

LP continues to suspend…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LPX Louisiana-Pacific
$31.40 /

-0.27 (-0.85%)

LPX Louisiana-Pacific
$31.40 /

-0.27 (-0.85%)

06/19/20 TD Securities
Louisiana-Pacific downgraded to Hold on valuation at TD Securities
06/19/20 TD Securities
Louisiana-Pacific downgraded to Hold from Buy at TD Securities
03/24/20 TD Securities
Louisiana-Pacific upgraded to Buy from Hold at TD Securities
01/21/20 Stephens
Louisiana-Pacific downgraded to Equal Weight from Overweight at Stephens
LPX Louisiana-Pacific
$31.40 /

-0.27 (-0.85%)

Periodicals
Trump says Microsoft can pursue TikTok acquisition, NY Times reports » 06:04
08/04/20
08/04
06:04
08/04/20
06:04
MSFT

Microsoft

$216.60 /

+11.605 (+5.66%)

President Trump says…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.